Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

  title={Assessment of second-line antiretroviral regimens for HIV therapy in Africa.},
  author={Nicholas I. Paton and Cissy M. Kityo and Anne Hoppe and Andrew L Reid and Andrew Ddungu Kambugu and Abbas Lugemwa and Joep J. van Oosterhout and Mary Kiconco and Abraham M. Siika and Raymond Mbayo Mwebaze and Mary C Abwola and George Abongomera and Aggrey Mweemba and Hillary Alima and Dickens Atwongyeire and Rose Kolola Nyirenda and Justine Boles and Jennifer Thompson and Dinah Tumukunde and Ennie Chidziva and Ivan K Mambule and Jos{\'e} Ram{\'o}n Arribas and Philippa Jane Easterbrook and James G Hakim and A Sarah Walker and Peter Mugyenyi},
  journal={The New England journal of medicine},
  volume={371 3},
BACKGROUND The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus (HIV) infection in resource-limited settings. Removing the NRTIs or replacing them with raltegravir may provide a benefit. METHODS In this open-label trial in sub-Saharan Africa, we randomly assigned 1277 adults and adolescents with HIV infection and first-line treatment… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 23 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 68 extracted citations


Publications referenced by this paper.
Showing 1-10 of 24 references

A randomized comparison of second - line lopinavir / ritonavir monotherapy versus tenofovir / lamivudine / lopinavir / ritonavir in patients failing NNRTI regimens : the HIV STAR study

  • DW Cameron, BA daSilva, Arribas
  • Antivir Ther
  • 2012

Similar Papers

Loading similar papers…